Jasper Therapeutics (JSPR)
(Delayed Data from NSDQ)
$18.10 USD
+0.12 (0.67%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $18.28 +0.18 (0.99%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Jasper Therapeutics, Inc. (JSPR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$72.14 | $90.00 | $55.00 | 301.22% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Jasper Therapeutics, Inc. comes to $72.14. The forecasts range from a low of $55.00 to a high of $90.00. The average price target represents an increase of 301.22% from the last closing price of $17.98.
Analyst Price Targets (7 )
Broker Rating
Jasper Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.10 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.10 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, nine are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 90% and 10% of all recommendations. A month ago, Strong Buy made up 90%, while Buy represented 10%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 7 | 7 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.10 | 1.10 | 1.10 | 1.13 | 1.13 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/5/2024 | H.C. Wainwright & Co. | Emily Bodnar | Strong Buy | Strong Buy |
7/31/2024 | Evercore Partners | Gavin Clark-Gartner | Strong Buy | Strong Buy |
7/8/2024 | BTIG | Justin R Zelin | Not Available | Strong Buy |
6/27/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/18/2024 | Cantor Fitzgerald & Co | Pete Stavropoulos | Strong Buy | Strong Buy |
6/10/2024 | Capital One Securities | Timothy Chiang | Strong Buy | Strong Buy |
3/28/2024 | Not Identified | Not Identified | Not Available | Moderate Buy |
3/4/2024 | William Blair | Matt Phipps | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.10 |
ABR (Last week) | 1.10 |
# of Recs in ABR | 10 |
Average Target Price | $72.14 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 80 of 253 |
Current Quarter EPS Est: | -1.13 |